AstraZeneca

AstraZeneca's Discovery Centre, built by Mace Group, fosters collaboration among 2,000 employees on Cambridge's Biomedical Campus, aiming to accelerate disease impact through data, AI, and precision medicine. The project's success highlights the importance of transparent collaboration in advancing science.

Osimertinib (Tagrisso; AstraZeneca) approved by FDA for treating unresectable, stage III, EGFRm NSCLC not progressed post-platinum-based CRT, based on phase 3 LAURA trial results.

Bispecific antibodies, designed to target two antigens simultaneously, are revolutionizing cancer treatment by enhancing antitumor immune responses and overcoming immune evasion mechanisms. The global market for these antibodies is projected to exceed USD 8 billion by 2023, driven by advancements in antibody engineering and increasing demand for targeted therapies. Major pharmaceutical companies are investing in bispecific antibody research, with strategic collaborations accelerating development. The market is expected to grow further due to expanding therapeutic applications and a shift towards personalized medicine.

AstraZeneca's FluMist, a nasal spray flu vaccine, is now approved for self-administration by adults up to 49 years old, with children aged 2-17 requiring a parent or caregiver. This approval aims to increase vaccination rates and accessibility, following a period of low effectiveness that led to a CDC recommendation against its use in 2016/2017.

BioCity Biopharma's SC0062, an ETA selective antagonist, received Breakthrough Therapy Designation from NMPA for treating IgA nephropathy with proteinuria, based on Phase 2 trial results showing significant reduction in proteinuria and favorable safety profile. The study continues for diabetic kidney disease cohort, with results expected in Q4.

Pharmaceutical companies have raised prices on over 1,000 drugs this year, disproportionately affecting Black and Latino patients aged 65 and over. Enhertu, used to treat HER2 negative breast cancer, has seen eight price hikes since 2019, reaching over $2,800 per month. Patients for Affordable Drugs calls the lack of affordability a 'crisis' disproportionately hurting people of color, who are more likely to suffer from chronic conditions requiring expensive drugs. Advocacy groups push for policies to lower drug prices, highlighting systemic racism in healthcare.

Arbeta heltid, dela föräldraledighet, se till tjänstepension, och starta eget pensionssparande för bättre pension. Kontakta Kundcenter Privat för hjälp.

Lung cancer is a leading cause of cancer death globally, with EGFRm NSCLC patients particularly sensitive to EGFR-TKI treatment. LAURA trial assessed Tagrisso in Stage III EGFRm NSCLC patients post-CRT, enrolling 216 patients across 15 countries. Tagrisso, a third-generation EGFR-TKI, has demonstrated efficacy in various NSCLC stages and is being explored in early-stage and resistant settings. AstraZeneca aims to improve lung cancer outcomes through early detection and innovative treatments.

The FDA approved the first at-home flu vaccine nasal spray, FluMist, available online with a prescription from next year, not recommended for those aged 50 and older. Experts predict increased vaccination rates due to convenience, though concerns exist over proper self-administration and storage. FluMist, containing attenuated live viruses, is not suitable for individuals with weakened immune systems or certain medical conditions.

Bloomberg connects decision makers to a dynamic network, delivering business and financial information globally.